John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Pharmaco-economic aspects of irritable bowel syndrome Volume 21, supplement 2, Septembre 2014

Tables

Authors
CHU Estaing,
service de médecine digestive,
1 Place Lucie Aubrac,
63000 Clermont-Ferrand,
France
* Tirés à part

The irritable bowel syndrome (IBS) is an association of abdominal pain and different patterns of transit disorders. The definition along Rome III criteria try to make a positive diagnosis of IBS. The prevalence is high wherever it is assessed. The lack of a definite biological marker leads to the prescription of a lot of complementary examinations. The quality of life is impaired in IBS and is clearly correlated with the severity of symptoms. All these points explain, at least in part, the economic burden of IBS on health care resources. The direct costs such as the number of medical consultations, drugs consumption, and the number and quality of complementary investigations are easier to evaluate than indirect costs represented by work absenteeism or altered presenteism which can have a major impact on the cost of IBS. Strong phamaco economic data which could explore the cost effectiveness of new management strategies in IBS are still lacking.